In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Alnylam Pharmaceuticals trades 41.2% above its PERT-weighted fair value of $174.06, indicating overvaluation by key metrics like DCF and P/E. High liquidity and profitability scores contrast with moderate leverage and growth, suggesting financial strength amid valuation concerns. Monte Carlo analysis shows zero downside risk below current price, implying limited near-term valuation correction scenarios.